Pharmaceuticals Denmark

Denmark Active Pharmaceutical Ingredients (API) Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Denmark Active Pharmaceutical Ingredients (API) Market Industry Trends and Forecast to 2034: Segmented by (Type, Source, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Denmark · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.02 Bn Placeholder estimate
Estimate 2025 $1.08 Bn 0.4% of the global market
Projected 2034 $1.74 Bn 61.9% Adds $666.7 Mn over 9 forecast years
CAGR 2025–2034 5.5% Faster than 40% of 5 Pharmaceuticals markets here
Key players 6 +1
  • Denmark is 0.44% of the global market.
  • In Europe, the largest is Germany at $8.11 Bn.
  • Fastest growing: Russia at 6.6% a year.
  • Denmark ranks 13th of 13 by size in Europe.

Market size projection

Denmark

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$666.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Active Pharmaceutical Ingredients (API) Market market size by year, Denmark
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.02 Bn — —
2025 (base) $1.08 Bn +$56.1 Mn —
2026 (forecast) $1.14 Bn +$59.2 Mn +5.5%
2027 (forecast) $1.20 Bn +$62.5 Mn +11.3%
2028 (forecast) $1.26 Bn +$65.9 Mn +17.4%
2029 (forecast) $1.33 Bn +$69.5 Mn +23.9%
2030 (forecast) $1.41 Bn +$73.4 Mn +30.7%
2031 (forecast) $1.48 Bn +$77.4 Mn +37.9%
2032 (forecast) $1.57 Bn +$81.7 Mn +45.5%
2033 (forecast) $1.65 Bn +$86.2 Mn +53.5%
2034 (forecast) $1.74 Bn +$90.9 Mn +61.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Denmark Active Pharmaceutical Ingredients (API) Market Analysis at a glance
Market size, 2025$1.08 Bn placeholder estimate
Forecast, 2034$1.74 Bn placeholder estimate
Growth (CAGR), 2025–20345.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType and source (see all)
Key playersLonza Ltd, Pfizer CentreOne, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical, Dr Reddy’s Laboratories and 1 more (see all)
Regulator in DenmarkDanish Medicines AgencySource: Danish Medicines Agency. Checked 19 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Denmark Active Pharmaceutical Ingredients (API) Market Analysis Executive Summary

Active pharmaceutical ingredients are the chemicals or biological substances in a medicine that give it its effect.

Key segments of the active pharmaceutical ingredients (API) market include type (Synthetic API, Biotech API and Highly Potent API) and source (Captive and Contract Manufactured).

Bar chart: Denmark Active Pharmaceutical Ingredients (API) market size, 2024–2034, placeholder estimates. $1.02 Bn in 2024, $1.08 Bn in 2025 and $1.74 Bn in 2034, 5.5% CAGR.
Denmark Active Pharmaceutical Ingredients (API) market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Denmark Active Pharmaceutical Ingredients (API) Market Dynamics

Market Growth Drivers

Ageing populations, more chronic disease, broader access to medicines and steady new drug approvals are driving the active pharmaceutical ingredients (API) market.

Opportunity

Personalized treatments, local manufacturing and new technologies for making medicines give the active pharmaceutical ingredients (API) market room to grow.

Market Restraints

Price controls, long and costly development, patent expiries and strict quality rules hold back the active pharmaceutical ingredients (API) market.

Competitive Landscape for Active Pharmaceutical Ingredients (API) Market in Denmark

The active pharmaceutical ingredients (API) market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Active Pharmaceutical Ingredients (API) Market in Denmark

Active Pharmaceutical Ingredients (API) in Denmark: rules and payment

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by the Danish Medicines Agency.⁠[1] Tax-funded public health care is free for residents and run by the regions; the Danish Medicines Agency decides which medicines get general reimbursement.⁠[1]

[1] Danish Medicines Agency. Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for active pharmaceutical ingredients (API). Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Denmark.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Active Pharmaceutical Ingredients (API) right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Active Pharmaceutical Ingredients (API) in context

Denmark compared

  • Health spending per person: 6,745 US$ per person (2024). World: 1,317 US$ per person (2023). 4th highest of the 13 countries we cover in Europe.[1]
  • Doctors: 4.50 per 1,000 people (2021). World: 1.86 per 1,000 people (2022). 3rd highest of the 13 countries we cover in Europe.[2]
  • People aged 65 and over: 21.1% of people (2025). World: 10.4% of people (2025). 5th highest of the 13 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Active Pharmaceutical Ingredients (API) market in Denmark?
Placeholder estimate: about $1.08 Bn in 2025, rising to about $1.74 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Active Pharmaceutical Ingredients (API) market in Denmark growing?
Placeholder estimate: about 5.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Active Pharmaceutical Ingredients (API) market report cover?
The report splits the market by type (Synthetic API, Biotech API, Highly Potent API) and source (Captive, Contract Manufactured).
Who are the key players in the Active Pharmaceutical Ingredients (API) market?
Key players include Lonza Ltd, Pfizer CentreOne, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical, Dr Reddy’s Laboratories and Cambrex.
What is driving the Active Pharmaceutical Ingredients (API) market?
Ageing populations, more chronic disease, broader access to medicines and steady new drug approvals are driving the active pharmaceutical ingredients (API) market.
Who regulates Active Pharmaceutical Ingredients (API) in Denmark?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by the Danish Medicines Agency. Source: Danish Medicines Agency. Checked 19 Nov 2026.
How is healthcare paid for in Denmark?
Tax-funded public health care is free for residents and run by the regions; the Danish Medicines Agency decides which medicines get general reimbursement. Source: Danish Medicines Agency. Checked 19 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Denmark

See all

Related on drug development and manufacturing

See the topic